| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TR; HTR; CF2R; PAR1; PAR-1 |
| WB Predicted band size | 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human F2R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于F2R(PAR1)抗体的3篇代表性文献摘要：
---
1. **文献名称**：*Targeting PAR1: Structural Insights into the Discovery of Novel Antiplatelet Agents*
**作者**：Zhang P. et al.
**摘要**：该研究解析了PAR1受体的三维结构，并开发了一种新型单克隆抗体，通过阻断凝血酶结合位点抑制血小板活化，为抗血栓治疗提供潜在策略。
2. **文献名称**：*A PAR1-Targeting Antibody Attenuates Murine Colitis by Suppressing Inflammation and Fibrosis*
**作者**：Chen L. et al.
**摘要**：研究证明，靶向PAR1的抗体可减少肠道炎症和纤维化，机制涉及抑制NF-κB通路和促炎因子释放，提示其在炎症性肠病中的治疗潜力。
3. **文献名称**：*PAR1 Antagonism by a High-Affinity Antibody Inhibits Tumor Metastasis in Vivo*
**作者**：Smith J.R. et al.
**摘要**：该抗体通过特异性结合PAR1胞外域，阻断肿瘤细胞迁移和血管生成，显著降低乳腺癌小鼠模型的肺转移率，为癌症治疗提供新方向。
---
以上文献聚焦PAR1抗体的结构开发、炎症抑制和抗肿瘤应用，均为近年研究(2018-2023)，涵盖基础机制与转化医学方向。如需具体期刊或DOI可进一步补充检索。
F2R, also known as protease-activated receptor 1 (PAR1), is a G protein-coupled receptor encoded by the F2R gene. It plays a critical role in mediating cellular responses to thrombin, a key enzyme in coagulation and inflammation. PAR1 is activated through proteolytic cleavage by thrombin, exposing a tethered ligand that triggers intracellular signaling pathways. This receptor is widely expressed in platelets, endothelial cells, and smooth muscle cells, influencing processes like platelet activation, vascular permeability, and inflammation. Dysregulation of PAR1 signaling has been linked to thrombotic disorders, atherosclerosis, and cancer metastasis.
F2R antibodies are tools or therapeutic agents targeting PAR1. In research, they are used to study receptor localization, activation mechanisms, and downstream effects. Therapeutically, PAR1 antagonists (including antibody-based inhibitors) have been explored to prevent pathological thrombosis while minimizing bleeding risks compared to conventional antiplatelet drugs. For example, vorapaxar, a small-molecule PAR1 antagonist, was approved for cardiovascular risk reduction but with limitations due to bleeding side effects. Antibody-based approaches aim to achieve higher specificity, potentially blocking specific PAR1 interactions involved in disease progression without disrupting hemostatic functions. Current studies also investigate F2R antibodies in oncology, as PAR1 overexpression correlates with tumor growth and metastasis in certain cancers. Challenges include optimizing selectivity and balancing antithrombotic efficacy with safety profiles.
×
